Deep Dive into Healthcare False Claims: Which Areas Are Being Actively Pursued by the Government

January 30, 2017 4:30pm

Margaret Hutchinson
Civil Chief
US Attorney’s Office, Eastern District of Pennsylvania

Brien O’Connor
Ropes & Gray, LLP (Boston, MA)

Thomas Crane
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo PC (Boston, MA)

Timothy Howard
Assistant Counsel
Merck Sharp & Dohme Corp. (Philadelphia, PA)

  • What the recent uptick of enforcement in the Specialty Pharma, Medical Device, Laboratory & Diagnostics and Scientific Grant Funding industries reveals about where companies are most at risk
  • Recent developments and trends in enforcement of the Anti- Kickback Statute and how this interfaces with False Claims Act enforcement
  • Why fraud under states’ Managed Care Medicaid programs will result in many more FCA cases
  • What PBM issues appear to interest Government regulators and enforcers?
  • What practical effect will the ruling in Escobar have on healthcare providers’ compliance programs?
  • Detailed look into the issue of medical necessity following the decision in US ex rel Paradies v AseraCare Inc that contradiction based on clinical judgment or opinion alone cannot constitute falsity under the FCA